Cargando…

Specialty and cancer drugs set to drive US drug expenditure in 2021

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085802/ https://www.ncbi.nlm.nih.gov/pubmed/33948077 http://dx.doi.org/10.1007/s40274-021-7669-0

Ejemplares similares

Management of specialty drugs, specialty pharmacies and biosimilars in the United States
por: Brook, Richard A., et al.
Publicado: (2019)

Price Increases and New Drugs Drive Increased Expenditures for Multiple Sclerosis
por: Schafer, Jeremy A., et al.
Publicado: (2010)

The association between US Food and Drug Administration−expedited review designations and health plan specialty drug coverage
por: Panzer, Ari D, et al.
Publicado: (2023)

Primary Immunodeficiency Diseases at Reference and High-Specialty Hospitals in the State of Guanajuato, Mexico
por: Guaní-Guerra, Eduardo, et al.
Publicado: (2013)

Drug utilization and expenditure of anticancer drugs for breast cancer
por: Balkhi, Bander, et al.
Publicado: (2020)

Drug-drug interactions in patients with COVID-19
Publicado: (2020)

Energy Expenditure and Physical Activity in Recovering Malnourished Infants
por: Rising, Russell, et al.
Publicado: (2010)

Resting Energy Expenditure in Anorexia Nervosa: Measured versus Estimated
por: El Ghoch, Marwan, et al.
Publicado: (2012)

To Drive or Not to Drive: Assessment Dilemmas for GPs
por: Sims, J., et al.
Publicado: (2012)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales
por: Chamberlain, C, et al.
Publicado: (2014)

COVID-19 QALY values differ between US EQ-5D-5L value sets
Publicado: (2021)

Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis
por: Cowey, Charles Lance, et al.
Publicado: (2021)

Reporting of Drug Expenditures in the MCBS
por: Poisal, John A.
Publicado: (2003)

Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2015)

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016)

Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent
por: Sukhatme, Vidula, et al.
Publicado: (2015)

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016)

Genotype by Energy Expenditure Interaction and Body Composition Traits: The Portuguese Healthy Family Study
por: Santos, D. M., et al.
Publicado: (2014)

Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Clinical Evaluation of the Appropriateness Use Criteria for Single-Photon Emission-Computed Tomography: Differences by Patient Population, Physician Specialty, and Patient Outcomes
por: Druz, Regina S., et al.
Publicado: (2011)

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
por: Atherly, A J, et al.
Publicado: (2012)

Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
por: Verbaanderd, Ciska, et al.
Publicado: (2017)

Drug interaction between hydroxychloroquine and metformin
Publicado: (2020)

SenseWear Armband and Stroke: Validity of Energy Expenditure and Step Count Measurement during Walking
por: Manns, Patricia J., et al.
Publicado: (2012)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study
por: Hamberg, P, et al.
Publicado: (2014)

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
por: Chavarri-Guerra, Y, et al.
Publicado: (2014)

Bone Mineral Density Accrual Determines Energy Expenditure with Refeeding in Anorexia Nervosa and Supersedes Return of Menses
por: Sum, Melissa, et al.
Publicado: (2011)

Hydroxychloroquine concentrations persist after drug discontinuation
Publicado: (2022)

Network-principled deep generative models for designing drug combinations as graph sets
por: Karimi, Mostafa, et al.
Publicado: (2020)

Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents
por: Pantziarka, Pan, et al.
Publicado: (2018)

Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions
por: Chambers, James D, et al.
Publicado: (2023)

Telemedicine improves drug adherence and reduces OOP costs
Publicado: (2021)

Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
por: Farazi, Aliasghar, et al.
Publicado: (2014)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

A Single Dose of Goji Berries Does Not Affect Postprandial Energy Expenditure and Substrate Oxidation in Healthy, Overweight Men
por: van den Driessche, José J., et al.
Publicado: (2019)

Limited role of patient input in specialty drug coverage policies
por: D’Cruz, Brittany, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uku6crlp9v48ov9e0u6hlvqqrd